Skip to main content

Temozolomide Side Effects

Medically reviewed by Last updated on Jan 24, 2024.

Applies to temozolomide: oral capsule. Other dosage forms:

Serious side effects of Temozolomide

Along with its needed effects, temozolomide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking temozolomide:

Less common or rare

Incidence not known

Other side effects of Temozolomide

Some side effects of temozolomide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common or rare

For Healthcare Professionals

Applies to temozolomide: intravenous powder for injection, oral capsule.


Very common (10% or more): Constipation (Up to 33%), nausea (Up to 53%), vomiting (Up to 42%), diarrhea (16%)

Common (1% to 10%): Abdominal pain, diarrhea, stomatitis, taste perversion, dysphagia, dyspepsia

Uncommon (0.1% to 1%): Abdominal distension, fecal incontinence, gastrointestinal disorder, gastroenteritis, hemorrhoids[Ref]


The most common side effects were alopecia, nausea, vomiting, anorexia, headache, and constipation.[Ref]

Nervous system

Very common (10% or more): Headache (Up to 41%), convulsions (Up to 23%), hemiparesis (18%), abnormal coordination (11%)

Common (1% to 10%): Dizziness, confusion, memory impairment, amnesia, paresthesia, somnolence, paresis, urinary incontinence, ataxia, abnormal gait, neuropathy, balance impairment, speech disorder, tremors, hemiparesis[Ref]


Very common (10% or more): Peripheral edema (11%)

Uncommon (0.1% to 1%): Palpitation[Ref]


Very common (10% or more): Fatigue (Up to 61%), asthenia (13%), fever (13%)

Common (1% to 10%): Weakness, radiation injury, face edema, pain, hearing impairment

Uncommon (0.1% to 1%): Otitis media, tinnitus, hyperacusis, earache, deafness, vertigo, impotence, vaginal hemorrhage, menorrhagia, amenorrhea, vaginitis, breast pain[Ref]


Common (1% to 10%): Adrenal hypercorticism[Ref]


Common (1% to 10%): Cough, dyspnea, upper respiratory tract infection, pharyngitis, sinusitis

Post-marketing surveillance: Interstitial pneumonitis, pneumonitis, alveolitis, pulmonary fibrosis[Ref]


Very common (10% or more): Alopecia (55 to 69%), rash (13 to 19%)

Common (1% to 10%): Dry skin, erythema, pruritus, petechiae

Uncommon (0.1% to 1%): Photosensitivity reaction, abnormal pigmentation, sweating increased

Post-marketing surveillance: Toxic epidermal necrolysis, Stevens-Johnson syndrome[Ref]

A case of diffuse erythematous skin rash that progressed to an extensive full body desquamative skin rash has been reported. Even though temozolomide was permanently discontinued, the patient continued to experience the rash on a long-term basis with periodic exacerbations.[Ref]


Common (1% to 10%): Insomnia, anxiety, depression

Uncommon (0.1% to 1%): Agitation, apathy, behavior disorder, hallucination, amnesia[Ref]


Very common (10% or more): Anorexia (19 to 27%)

Common (1% to 10%): Weight increase, weight decrease, hyperglycemia

Uncommon (0.1% to 1%): Hypokalemia[Ref]


Common (1% to 10%): Arthralgia, back pain[Ref]


Common (1% to 10%): Vision blurred, diplopia

Uncommon (0.1% to 1%): Hemianopia, visual acuity reduced, vision disorder, visual field defect, eye pain, dry eyes[Ref]


Common (1% to 10%): Infection, Herpes simplex, wound infection, candidiasis oral

Uncommon (0.1% to 1%): Herpes zoster, influenza-like symptoms

Post-marketing surveillance: Opportunistic infections including Pneumocystis pneumonia[Ref]


Post-marketing surveillance: Secondary malignancies including myeloid leukemia[Ref]


Common (1% to 10%): Thrombocytopenia, hemorrhage, leukopenia, neutropenia, lymphopenia, febrile neutropenia, anemia

Post-marketing surveillance: Prolonged pancytopenia, myelodysplastic syndrome[Ref]


Common (1% to 10%): ALT increased

Uncommon (0.1% to 1%): Hepatic enzymes increased, Gamma GT increased, AST increased

Post-marketing surveillance: Fatal and severe hepatotoxicity, elevation of liver enzymes, hyperbilirubinemia, cholestasis, hepatitis


Common (1% to 10%): Allergic reaction


Common (1% to 10%): Urinary tract infection, micturition increased frequency

Uncommon (0.1% to 1%): Dysuria


1. Product Information. Temodar (temozolomide). Schering Corporation. 2001;PROD.

2. Pick AM, Neff WJ, Nystrom KK. Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma. Pharmacotherapy. 2008;28:406-9.

3. Villano JL, Collins CA, Manasanch EE, Ramaprasad C, van Besien K. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol. 2006;7:436-8.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.